This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Cervical Spina Bifida with Hydrocephalus수두증을 동반한 경추 이분척추 (수두증 반 경추 이분척추)

Contents and key points
ItemDetails
A. Classification codesICD-10: Q05.0 | Special Copayment Reduction: V179
B. SynonymsCervical spina bifida with hydrocephalus
C. Adult onsetVery low — as a congenital spinal malformation, it is in principle diagnosed in the fetal or neonatal period; first onset in adulthood is extremely rare.
1. HistoryHistorical development of spina bifida; first named by Tulp in 1641 → 1991 MRC folic acid study → 2011 MOMS fetal surgery trial.
2. CausesFolate deficiency, multifactorial inheritance, maternal diabetes, obesity, anticonvulsants; hydrocephalus: impaired cerebrospinal fluid flow due to Chiari II malformation.
3. GeneticsMTHFR, PCP pathway genes; multifactorial inheritance; recurrence risk 2–5%; high-dose folic acid supplementation for high-risk groups.
4. General epidemiology1 in 1,000–2,000 births; cervical spina bifida is the rarest location; rate of associated hydrocephalus nearly 100%.
5. PathophysiologyFailure of neural tube closure; two-hit theory; mechanisms of Chiari II malformation and hydrocephalus; risk of respiratory paralysis with cervical lesions.
6. SymptomsQuadriplegia, respiratory failure (upper cervical), hydrocephalus symptoms, neurogenic bladder and bowel, risk of pressure ulcers; the most severe form of spina bifida.
7. SignsCystic cervical defect, loss of limb movement, respiratory paralysis, signs of hydrocephalus, findings of Chiari II malformation.
8. ScreeningMSAFP, detailed prenatal ultrasound (lemon and banana signs), fetal MRI; precise assessment of lesion level.
9. DiagnosisPrenatal confirmation; postnatal neurological evaluation; brain and spine MRI; urological evaluation; respiratory function evaluation.
10. TreatmentPrenatal/postnatal spinal cord closure; VP shunt; mechanical ventilation; CIC; orthopedic treatment; multidisciplinary rehabilitation.
11. PrognosisPoorest among spina bifida forms; quadriplegia and ventilator dependence; hydrocephalus management determines cognitive prognosis.
12. PreventionFolic acid supplementation (general 400–800 μg; high-risk 4,000 μg); risk factor management; detailed prenatal testing.
13. ReferencesMitchell LE et al. 2004 and 9 other references

1. History

Spina bifida is one of the oldest congenital malformations in the history of human medicine. Spina bifida findings have been found in Egyptian mummies from around 2500 BC, and descriptions of spinal abnormalities also exist in ancient Greek and Roman medical literature. The term 'spina bifida' is known to have been first used in 1641 by the 17th-century Dutch physician Nicolaas Tulp (1593–1674), expressing in Latin the condition of a vertebra split in two. In the early 18th century, the Italian anatomist Giovanni Battista Morgagni described the pathological anatomy of spina bifida in detail and was the first to point out the association between spinal cord exposure and hydrocephalus.

In the 19th century, surgical treatment of myelomeningocele was attempted along with advances in neurosurgical technique, but results were very poor because of infection in the pre-antibiotic era and technical limitations. Until the early 20th century, most patients with spina bifida and hydrocephalus died within a few years. In the 1950s–60s, the development of the ventriculoperitoneal shunt, the introduction of antibiotics, and improvements in anesthesia dramatically improved treatment outcomes.

In 1965, Hibbard and Smithells first proposed an association between folate deficiency and neural tube defects, and in 1991 the UK MRC Vitamin Study confirmed in a randomized controlled trial that folic acid supplementation before pregnancy reduces recurrence of neural tube defects by about 72%. Mandatory folic acid fortification of grain products was subsequently implemented in countries worldwide, greatly lowering the incidence of spina bifida.

The 2011 MOMS (Management of Myelomeningocele Study) randomized controlled trial demonstrated that prenatal closure of myelomeningocele by fetal surgery at 19–25 weeks of gestation, compared with postnatal surgery, reversed Chiari II malformation, reduced the need for hydrocephalus shunting, and improved lower limb motor function. This was a landmark study that shifted the paradigm of spina bifida treatment.

For spina bifida with hydrocephalus (Q05.0–Q05.4), management within a multidisciplinary spina bifida clinic, with collaboration among pediatric neurosurgery, neurology, urology, orthopedics, rehabilitation medicine, and developmental pediatrics, has now become the worldwide standard. In Korea, multidisciplinary spina bifida clinics are also operated mainly at major children's hospitals, and the Korea Spina Bifida Association carries out support activities for patients and families.


2. Causes

Spina bifida is a neural tube defect (NTD) caused by failure of the neural tube closure process in early pregnancy (about 17–30 days after fertilization, 5–6 weeks of gestation). Its causes are divided into genetic factors, maternal nutritional and metabolic factors, environmental factors, and multifactorial interactions.

Folate deficiency: folic acid deficiency in early pregnancy is the best-known preventable cause of spina bifida. Folic acid is an essential nutrient for DNA synthesis, cell division, and one-carbon metabolism, and deficiency impairs the neural tube closure process, in which rapid cell division occurs. There is strong epidemiological evidence that folic acid supplementation before pregnancy lowers the incidence of spina bifida by about 50–70%.

Genetic factors: spina bifida is a multifactorial disease not explained by a single gene variant. The MTHFR 677C→T polymorphism, folate receptor gene variants, and variants in planar cell polarity (PCP) pathway genes (VANGL1, VANGL2, etc.) are associated with increased risk of spina bifida. With a family history, the recurrence risk is about 4–8 times that of the general population.

Maternal factors: maternal diabetes (poor glycemic control in early pregnancy), maternal obesity (BMI > 30), use of anticonvulsants (valproic acid, carbamazepine), and high fever in early pregnancy (38°C or higher) increase the risk of spina bifida. Valproic acid is known to increase the risk of neural tube defects about 10-fold, so special caution is needed when prescribing it to women of childbearing potential.

Etiology of spina bifida with hydrocephalus: hydrocephalus arises through combined mechanisms including Chiari II malformation (herniation of the cerebellum and brainstem through the foramen magnum), aqueductal stenosis, and fourth ventricle outlet obstruction. The higher the lesion level (cervical > thoracic > lumbar > sacral), the more severe the Chiari II malformation and the higher the rate and severity of associated hydrocephalus.


3. Genetics

Spina bifida is a disease of multifactorial inheritance, arising from complex interactions of multiple genetic polymorphisms and environmental factors rather than a single gene mutation. The risk of recurrence within families is higher than in the general population, but it does not follow a typical Mendelian pattern of inheritance.

Folate metabolism genes: the MTHFR (methylenetetrahydrofolate reductase) c.677C→T polymorphism (p.Ala222Val) is known to reduce enzyme activity by 30–65% and to increase the risk of spina bifida 1.5–2-fold through elevated blood homocysteine. Variants in other folate metabolism enzyme genes such as FOLR1 (folate receptor 1) and MTHFD1 are also associated with neural tube defects.

Planar cell polarity (PCP) pathway genes: PCP genes such as VANGL1 (1p13.1), VANGL2 (1q22-q23), CELSR1, FZD3, and SCRIB are essential for orienting neural plate cells and for convergent extension movements during neural tube closure. PCP gene variants are found in about 1–3% of patients with spina bifida.

Recurrence risk: for parents with 1 child with spina bifida, the recurrence risk in the next pregnancy is about 2–5%. With 2 affected children, about 10–15%. If one parent has spina bifida, the risk for children is about 4–8%. In high-risk groups, high-dose folic acid (4,000 μg/day) supplementation from before pregnancy greatly reduces the risk of recurrence. Preimplantation genetic testing (PGT) is considered only in limited cases where a specific single-gene cause has been identified.


4. General epidemiology

Spina bifida is the most common neural tube defect worldwide, occurring in about 1 in 1,000–2,000 births. Incidence by country differs greatly depending on folic acid supplementation policies and the rate of pregnancy termination after prenatal diagnosis. In the United States, the incidence of neural tube defects fell by about 26–28% after mandatory folic acid fortification of grains (1998).

For spina bifida with hydrocephalus (Q05.0–Q05.4), hydrocephalus is reported to accompany about 80–90% of all open spina bifida. The higher the lesion level (cervical > thoracic > lumbar > sacral), the higher the rate of associated hydrocephalus; in cervical and upper thoracic lesions in particular, hydrocephalus is present in nearly 100%. Sex differences are slight, and some studies report a female predominance. The incidence in Korea is estimated at about 4–6 per 10,000 births, and the prenatal diagnosis rate has risen since prenatal ultrasound became widespread. Registration under Special Copayment Reduction V179 allows medical cost support.


5. Pathophysiology

Spina bifida arises from failure of neural tube closure at about 17–30 days of gestation. Neural tube closure begins simultaneously at several initiation sites and proceeds like a zipper, and failure of closure at each site causes a different type of neural tube defect. Failure of closure of the spinal portion of the neural tube causes spina bifida, and depending on the extent and location of the closure failure, the characteristics of cervical (Q05.0), thoracic (Q05.1), lumbar (Q05.2), and sacral (Q05.3) spina bifida differ.

Two-hit hypothesis: the neurological impairment of myelomeningocele consists of two components: ① the primary developmental defect caused by the failure of neural tube closure itself, and ② secondary damage (physical compression, chemical injury, inflammation) from exposure of the open spinal cord to amniotic fluid in utero. The MOMS trial (2011) confirmed that prenatal repair (fetal surgery) reduces the secondary damage and improves neurological outcome, clinically validating this theory.

Chiari II malformation and hydrocephalus: as the spinal cord herniates out of the spinal canal, cerebrospinal fluid flow within the spinal canal changes and the posterior fossa develops small, forming the Chiari II malformation, in which the cerebellar tonsils, vermis, and lower brainstem herniate downward through the foramen magnum. This causes aqueductal stenosis and fourth ventricle outlet obstruction, leading to non-communicating hydrocephalus. The higher the lesion level, the more severe the Chiari II malformation and the higher the rate of associated hydrocephalus.

Mechanism of neurogenic bladder and bowel: loss of function of spinal nerves below the lesion level (S2–S4 sacral nerves) impairs neural control of the bladder and rectum. This results in a neurogenic bladder with reduced bladder capacity, bladder overactivity, and abnormal urethral sphincter control; ascending urinary tract infection and declining renal function are the main complications.


6. Symptoms

Cervical spina bifida with hydrocephalus has the highest spinal lesion (cervical) of all spina bifida types and clinically shows the most severe neurological deficits. Loss of spinal cord function at the cervical level causes quadriplegia, i.e., loss of motor and sensory function in both the upper and lower limbs, and autonomic nervous system dysfunction may also be severe.

Quadriplegia/tetraplegia: loss of function of spinal nerves below the cervical lesion level causes weakness or complete paralysis and sensory loss in both the upper and lower limbs. The extent of paralysis varies with the cervical level, and in upper cervical (C1–C4) lesions, respiratory failure due to respiratory muscle paralysis can be life-threatening.

Respiratory dysfunction: when diaphragmatic innervation is damaged in lesions at or above the upper cervical (C3–C5) level, spontaneous breathing may be impossible or severely reduced, and mechanical ventilation may be needed. This is a major reason why survival in cervical spina bifida is markedly lower than in spina bifida at other levels.

Symptoms of hydrocephalus: symptoms of raised intracranial pressure due to hydrocephalus (macrocephaly, bulging fontanelle, nausea and vomiting, decreased consciousness, sunset sign) are present. In cervical spina bifida, Chiari II malformation tends to be severe, so dysphagia, respiratory abnormalities, and hoarseness due to brainstem compression may be present.

Neurogenic bladder and bowel: loss of sacral nerve control below the lesion causes neurogenic bladder (urinary incontinence, risk of urinary tract infection) and neurogenic bowel (constipation, fecal incontinence). This problem occurs equally in lumbar and sacral spina bifida, but in cervical lesions, hyperreflexic bladder due to upper motor neuron damage is more common.

Risk of pressure ulcers: because of complete paralysis and sensory loss, the risk of pressure ulcers is very high. Continuous repositioning, use of pressure-relieving bedding and aids, and skin care are essential.


7. Signs

Physical findings in patients with cervical spina bifida are very serious, and immediate neurosurgical evaluation is needed at birth.

Spinal defect findings: a cystic structure (myelomeningocele) or an open neural placode is observed in the neck. Skin defects of the neck and exposed neural tissue are characteristic. Depending on lesion size and location, abnormal head and neck posture may be seen.

Neurological findings: immediately after birth, absent or markedly reduced limb movement, absent deep tendon reflexes, and absent anal reflex are found. In upper cervical lesions, respiratory muscle paralysis requiring respiratory support may occur. Cranial nerve abnormalities (dysphagia, vocal cord paralysis due to medullary compression) are present.

Signs of hydrocephalus: macrocephaly, bulging anterior fontanelle, suture diastasis, and the sunset sign appear. Irritability, dysphagia, and apnea may be observed owing to upper cervical compression from Chiari II malformation.

Imaging findings: MRI shows the level and extent of the cervical neural defect, myelomeningocele or myelocele, Chiari II malformation (downward herniation of the cerebellar tonsils through the foramen magnum, compression of the medulla and cervical cord), and ventricular enlargement. Spinal MRI also evaluates associated syringomyelia and tethered cord.


8. Screening

A prenatal screening system for spina bifida is established, and a multi-tier screening strategy is used.

Maternal serum alpha-fetoprotein (MSAFP): on MSAFP testing at 15–22 weeks of gestation, ≥ 2.0–2.5 MoM is the positive threshold, detecting about 80–85% of open myelomeningoceles. MSAFP may be normal in closed or skin-covered spina bifida. If positive, confirm with detailed ultrasound.

Detailed prenatal ultrasound: detailed ultrasound at 18–22 weeks of gestation is the key screening tool. Characteristic findings are identification of the spinal defect, the 'lemon sign' (frontal bone scalloping), the 'banana sign' (cerebellar deformity due to Chiari II), and ventriculomegaly. Sensitivity for detecting open spina bifida is 95% or higher. Assessment of lesion level and associated anomalies is important for prognostic counseling.

Fetal MRI: performed additionally when prenatal ultrasound is abnormal, to precisely assess the lesion level, degree of Chiari II malformation, severity of hydrocephalus, and associated brain malformations. Accurate determination of the lesion level is important for surgical decisions (fetal surgery vs postnatal surgery) and prognostic counseling.

Amniotic fluid AFP and AChE testing: when ultrasound findings are unclear, amniotic fluid AFP and acetylcholinesterase (AChE) are measured by amniocentesis. Both markers are significantly elevated in open neural tube defects.


9. Diagnosis

Diagnosis of spina bifida requires a comprehensive approach including neuroimaging, neurological evaluation, and urological and orthopedic evaluation.

Prenatal diagnosis: confirm with a stepwise approach of MSAFP screening → detailed ultrasound → fetal MRI, and establish a pregnancy management plan with the multidisciplinary team. Prenatal genetic counseling (including chromosomal microarray testing) is also recommended.

Neonatal neurological evaluation: immediately after birth, determine the lesion level and evaluate lower limb motor function and sensation, anal reflex, and bladder function. The degree of loss of neurological function below the lesion level determines the functional prognosis.

Brain MRI and cranial ultrasound: brain ultrasound or MRI is performed after birth to evaluate hydrocephalus. Identify Chiari II malformation, ventricular size, and associated brain malformations, and assess indications for early shunting.

Spinal MRI: evaluates the lesion level and extent, tethered cord, syringomyelia, and abnormalities of spinal structures. Follow-up MRI checks for spinal cord retethering and progression of syringomyelia.

Urological evaluation: neurogenic bladder is evaluated by urinary tract ultrasound, voiding cystourethrography (VCUG), and urodynamics. Starting CIC early is important to protect renal function.

Orthopedic evaluation: evaluate hip dislocation, clubfoot, scoliosis and kyphosis, etc., and plan assistive device and surgical treatment.


10. Treatment

Treatment of spina bifida with hydrocephalus requires a multidisciplinary approach including prenatal or postnatal closure of the spinal defect, hydrocephalus surgery, neurogenic bladder management, orthopedic treatment, and neurodevelopmental support.

Myelomeningocele closure surgery: Prenatal surgery (fetal surgery): based on the MOMS trial (2011), performed at 19–25 weeks of gestation in selected cases; it reverses Chiari II malformation, reduces the need for hydrocephalus shunting, and improves lower limb motor function. Postnatal surgery: closure of the spinal defect within 24–48 hours after birth, aimed at preventing infection and further nerve damage.

Treatment of hydrocephalus: ventriculoperitoneal shunt (VP shunt) is the standard treatment, performed for progressive ventricular enlargement and raised intracranial pressure. Endoscopic third ventriculostomy (ETV) ± choroid plexus cauterization (CPC) is performed in some patients as an alternative to shunting. Shunt malfunction and infection are major complications requiring continuous follow-up.

Neurogenic bladder management: clean intermittent catheterization (CIC) is the key to protecting renal function. Anticholinergics (oxybutynin, solifenacin) increase bladder capacity and improve incontinence. When needed, bladder augmentation, urinary diversion, or intravesical Botox injection is performed.

Orthopedic treatment: hip dislocation, clubfoot, and scoliosis and kyphosis are treated with orthoses (AFO, KAFO), casting, and surgical correction. Early gait training is important for maintaining bone density and improving quality of life.

Rehabilitation and developmental support: physical therapy, occupational therapy, speech therapy, neuropsychological assessment, and learning support are essential. Regular follow-up (1–2 times a year) at a multidisciplinary spina bifida clinic is recommended.


11. Prognosis

Cervical spina bifida with hydrocephalus is the type of spina bifida with the poorest prognosis. In high cervical lesions the risk of death from respiratory paralysis is high, and even surviving patients have a combination of quadriplegia, severe hydrocephalus, and abnormal central respiratory control, making independent living almost impossible.

Survival: cervical spina bifida has the lowest incidence of all spina bifida and a high mortality due to natural history or limits of treatment. In the modern neonatal intensive care setting, some patients survive with aggressive treatment, but quadriplegia and ventilator dependence often persist.

Neurological prognosis: complete loss of motor and sensory function below the cervical lesion is mostly permanent. Whether some upper limb function is preserved depends on the exact lesion level, and some upper limb function may remain in lesions at or below C4. Cognitive function depends on hydrocephalus management and associated brain malformations, and early shunting and prevention of brain compression are important.

Respiratory prognosis: in lesions at or above C3–C5, long-term ventilator dependence greatly limits the prognosis. When nocturnal ventilatory support or full-time mechanical ventilation is needed, quality of life is markedly reduced, but with appropriate support, living at home is possible in some cases.

Shunt complications: in cervical spina bifida as well, hydrocephalus shunt-related complications (malfunction, infection) are a major cause of death and morbidity. Lifelong multidisciplinary follow-up is needed.


12. Prevention

The most effective primary prevention of spina bifida is folic acid supplementation before and in early pregnancy.

Folic acid supplementation: General population: 400–800 μg daily from at least 1 month before pregnancy until 12 weeks of gestation. High-risk groups (previous pregnancy with a neural tube defect, family history, diabetes, anticonvulsant use): high-dose supplementation of 4,000 μg (4 mg) daily from before pregnancy until 12 weeks of gestation is recommended. Get enough folate from fortified foods (cereals, flour, pasta) and natural foods such as green and yellow vegetables and legumes.

Management of risk factors before pregnancy: optimal glycemic control in maternal diabetes, weight management in obese mothers, switching women on anticonvulsants (valproic acid, etc.) to other drugs where possible or adjusting to the minimum dose, and avoiding high fever in early pregnancy contribute to prevention.

Prenatal care and genetic counseling: diagnose early with MSAFP screening, detailed ultrasound, and fetal MRI, and plan the pregnancy and delivery with the multidisciplinary team. With a family history, consider genetic counseling and preimplantation genetic testing (PGT).

Prevention of complications: early surgery (spinal cord closure, shunting) prevents secondary nerve damage and infection. Early introduction of CIC protects renal function. Regular multidisciplinary follow-up allows early detection and management of spinal cord retethering, shunt malfunction, and urological complications.

13. References

  1. Mitchell LE, Adzick NS, Melchionne J, et al. Spina bifida. Lancet. 2004;364(9448):1885-1895. PMID: 15555669.
  2. Adzick NS, Thom EA, Spong CY, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele (MOMS trial). N Engl J Med. 2011;364(11):993-1004. PMID: 21306277.
  3. Copp AJ, Stanier P, Greene NDE. Neural tube defects: recent advances, unsolved questions, and controversies. Lancet Neurol. 2013;12(8):799-810. PMID: 23790957.
  4. Northrup H, Volcik KA. Spina bifida and other neural tube defects. Curr Probl Pediatr. 2000;30(10):313-332. PMID: 11147289.
  5. Blount JP, Bowman R, Dias MS, et al. Neurosurgery in spina bifida. J Pediatr Rehabil Med. 2020;13(4):565-576. PMID: 33252094.
  6. Bowman RM, McLone DG, Grant JA, et al. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg. 2001;34(3):114-120. PMID: 11359098.
  7. Liptak GS, Dosa NP. Myelomeningocele. Pediatr Rev. 2010;31(11):443-450. PMID: 21041162.
  8. Bol KA, Collins JS, Kirby RS. Survival of infants with neural tube defects in the presence of folic acid fortification. Pediatrics. 2006;117(3):803-813. PMID: 16510665.
  9. Jukic AM, Wilcox AJ, Lie RT, et al. Spina bifida and the risk of stillbirth in Norway. Am J Epidemiol. 2004;160(10):1001-1008. PMID: 15522861.
  10. Williams LJ, Rasmussen SA, Flores A, et al. Decline in the prevalence of spina bifida and anencephaly by race/ethnicity: 1995-2002. Pediatrics. 2005;116(3):580-586. PMID: 16140698.